Regulatory Roundup for the Week of January 28, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup for the Week of January 28, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

  • ISPE has updated its ISPE GAMP guidance on testing of GXP systems to help companies efficiently test computerized and software-based systems.
  • France has asked the European Medicines Agency (EMA) to review third- and fourth-generation combined oral contraceptives to determine if these drugs should be restricted to women who cannot take other combined oral contraceptives. The agency’s Pharmacovigilance Risk Assessment Committee will review the drugs and give its opinion and determine if a EU-wide recommendation is necessary.
  • EMA has published guidance on preparing and reviewing product characteristic summaries. The guidance outlines the European Commission’s principles on product characteristic summaries.
  • EMA announced an agreement for collaboration with Israel on industrial standards. The agreement includes “the mutual recognition of the conclusions of GMP inspections, of manufacturing and import authorizations, and of certification of conformity of each batch without rechecking at import.”
  • The United States Pharmacopeial Convention (USP) has posted a revision bulletin on <232> Elemental Impurities—Limits and <233> Elemental Impurities—Procedures.
  • FDA has announced its Vaccines and Related Biological Products Advisory Committee Meeting will be held on Feb. 27, 2013. FDA is accepting public participation in the way of written submissions to be made on or before Feb. 20 and oral presentations that can be scheduled for Feb. 27, 2013.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here